Category WHO

Human Rights Go Hand In Hand With IP In Making Health Systems Work, UN Forum Hears

Innovation is vital for the development of medicines, but innovation without proper access to them is pointless, Roberto Azevêdo, Director-General of World Trade Organization has said. Several other agency heads spoke at the same event, where World Health Organization Director General Tedros Adhanom Ghebreyesus stressed the importance of universal health coverage.

Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest

NEW YORK -- In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the UN and foundations announced what they called a breakthrough pricing agreement that will speed the availability of "the first affordable, generic, single-pill HIV treatment regimen containing [the key compound] dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year." A senior official at Unitaid, the drug purchasing mechanism that helped reach the deal, explained to Intellectual Property Watch how it came about and why this is significant.

Key IP Delegates In Geneva – Fully Updated!

Geneva, Switzerland is the gathering point for the world's governments to set international policy and practices relating to intellectual property rights, as they cut across many of the public policy issues of the day (eg innovation, trade, internet, health, food), including at the World Intellectual Property Organization, World Trade Organization and World Health Organization. Everyone has a stake in what governments and their stakeholders do in these venues. But who do you talk to in order to get your message through? Now Intellectual Property Watch has fully updated its unique list of the diplomats representing many of the key nations in those institutions in Geneva. Available here for subscribers only!

Report From WHO Fair Pricing Meeting Shows Balanced Discussion

A wide range of governments and stakeholders attended a closed meeting in the Netherlands in May to address the ongoing problem of pricing medicines to pay for research and the resulting lack of affordability of those medicines. The report from the World Health Organization-led meeting shows a range of points were made by participants and signals a move to change the global policy.

The Case For Nations To Act On Medicines Access

NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead?

WHO Prequalifies First Generic Hepatitis C Drug And First HIV Self-Test

In the days before this month's AIDS conference being held in Paris, the World Health Organization has announced the prequalification of the first generic version of sofosbuvir, a "critical" medicine for treating hepatitis C. Treatment for hepatitis C under patent has been notoriously priced at extreme high levels, putting it out of reach of patients in economies of all sizes.